Transcriptome-based management and therapeutic intervention of chronic lung allograft dysfunction.

We aim to establish a comprehensive catalogue of the molecular determinants driving CLAD onset and progression, while also distinguishing discrepancies between the two main phenotypes of Chronic Lung Allograft Dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS).

By assessing the transcriptome of BOS and RAS in end-stage lung tissue, we expect to identify a possible common or phenotype-specific gene signature.

Based on this signature, we will investigate novel, more accurate diagnostic markers, which we will also validate in serial clinical samples of BOS and RAS patients (transbronchial biopsy, broncho-alveolar lavage and blood samples) using multiplex methodology, thereby assessing possible clinical applicability.

Moreover, we aim to propose novel/repurposed therapies based on the observed signature, which may allow for adequate disease prevention and/or more effective disease control.

Ultimately, we aspire that this project will result in improved (personalized) medical management of lung transplant patients at risk for – or with established – CLAD and thereby also help in providing better outcomes for cystic fibrosis patients, enabling them to live long and fulfilling lives.